ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

分组1 - ResMed reported quarterly earnings of $2.37 per share, exceeding the Zacks Consensus Estimate of $2.36 per share, and up from $2.13 per share a year ago, representing an earnings surprise of 0.42% [1] - The company achieved revenues of $1.29 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.53%, compared to $1.2 billion in the same quarter last year [2] - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has declined approximately 6.4% since the beginning of the year, while the S&P 500 has decreased by 10.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.45 on revenues of $1.32 billion, and for the current fiscal year, it is $9.47 on revenues of $5.11 billion [7] - The Zacks Industry Rank for Medical - Products is in the bottom 26% of over 250 Zacks industries, indicating potential challenges for stock performance [8]